NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) — DSS, Inc. (NYSE American: DSS) (the “Company”), a multinational company operating across diverse industries including product packaging, biotechnology, commercial lending, and securities and investment management, today announced that after further consideration, the Company determined not to proceed with its previously announced proposed public offering of Common Stock due to the limited capacity available under its existing shelf registration statement. The Company continues to evaluate its capital-raising alternatives and remains committed to creating value for shareholders. The Company’s Common Stock is traded on the NYSE American LLC under the symbol “DSS”. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, and no offering...

Lleida.net at CIS 2026 GCCM Almaty fraud prevention panelSisco Sapena, CEO of Lleida.net, takes part in the panel “Network APIs and Fraud Prevention: Strengthening Digital Trust Through Open Network Intelligence” at CIS 2026 GCCM Almaty, held in Almaty, Kazakhstan, on September 4, 2026.Almaty, KAZAKHSTAN, September 4, 2026.- Technology services company Lleida.net (BME:LLN, EPA:ALLLN) has presented its digital certification services in Kazakhstan for the first time, on the occasion of its participation in CIS 2026 GCCM Almaty, held from September 2 to 4 at the Royal Tulip Hotel in Almaty. Organized by Carrier Community (CC), CIS GCCM Almaty is holding its ninth annual meeting this year and is one of the leading gatherings for the wholesale telecommunications community. The event brings together more than 400 members...

$75 million funded upfront with an additional $325 million tied to milestones, providing strategic flexibility through anticipated value inflection points CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it has entered into a $400 million non-dilutive senior secured term loan facility with OrbiMed, a leading global healthcare investment firm. The transaction provides Intellia with greater financial and operational flexibility as it advances toward several key milestones, including a planned U.S. approval and commercial launch of lonvoguran ziclumeran (lonvo-z) as a one-time treatment for patients with hereditary angioedema (HAE). “Lonvo-z...

Expands Nanox’s growing U.S. distribution network with a leading New England-based medical imaging provider PETACH TIKVA, Israel — September 4 2026 — Nano-X Imaging Ltd. (“Nanox”, or the “Company”, NASDAQ: NNOX), a leader in innovative medical imaging technology, today announced that its U.S.-based subsidiary, Nanox Impact Inc., has entered into a distribution agreement with Associated X-Ray Imaging Corp., a New England-based provider of medical imaging equipment and services, specializing in X-ray, MRI, and CT systems, to support deployment of the Nanox.ARC across the region. Under the agreement, Associated X-Ray Imaging will market, distribute, and support the Nanox.ARC, an FDA-cleared, multisource 3D digital tomosynthesis system, leveraging its established regional presence and service infrastructure across New England. The collaboration...

Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt’s disease, a potentially blinding disease with no FDA-approved therapy Strengthens Tarsus’ differentiated pipeline and leadership in eye care IRVINE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that it has completed its previously announced acquisition of Alkeus Pharmaceuticals, Inc., a privately held retinal disease-focused biotechnology company. With the completion of the acquisition, Tarsus adds worldwide rights to ALK-001, a new, investigational, late-stage molecular entity designed to reduce the accumulation of toxic dimers while preserving the normal visual cycle. Tarsus believes ALK-001 represents a potential blockbuster opportunity...

Miami Beach, Florida, Sept. 04, 2026 (GLOBE NEWSWIRE) — Cuentas, Inc. (OTCQB: CUEN) (“Cuentas” or the “Company”), a cellular-focused technology company developing and expanding its mobile connectivity and digital services platform, today announced its financial results for the second quarter ended June 30, 2026, and announced it has over 4,000 active mobility customers. The Company’s second-quarter filing reflects continued progress in the transformation of Cuentas toward a mobility-centered operating model, including the development and commercialization of its mobile services platform through its majority-owned World Mobile LLC joint venture. Building a Scalable Cellular-Mobility Platform Cuentas holds a 51% membership interest in World Mobile LLC, its joint venture with World Mobile Group, and consolidates World Mobile LLC for...

PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) — UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 19 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of JELMYTO® (mitomycin) for pyelocalyceal solution and ZUSDURI™ (mitomycin) for intravesical solution, UroGen’s only approved products, and the continued development of UroGen’s pipeline. Up to 117,100 ordinary shares of UroGen are issuable upon the vesting and settlement of the RSUs. The RSUs will vest equally over three years, with one-third of the underlying shares vesting each year on the anniversary of...

FORT LAUDERDALE, Fla., Sept. 04, 2026 (GLOBE NEWSWIRE) — EdgeMode, Inc. (OTC: EDGM) today announces that, by mutual agreement with BlackBerry AIF and BLACK AI Group, the current review process between the parties will be extended for an additional period of up to six months. During this period, BLACK AI Group will continue to advance independently with the development of its AI infrastructure platform, including its large-scale data center projects, strategic partnerships, and financing strategy. The parties remain aligned around the opportunities within the AI infrastructure sector and will use this additional period to complete their strategic, corporate, and commercial review, while EdgeMode undertakes the internal corporate, financial, and strategic work required to support any potential future transaction. Potential structures...